Bristol-Myers Squibb (BMS) has partnered with Lupus Research Alliance and Lupus Therapeutics to evaluate a new investigational therapy, BMS-986165, for lupus erythematosus.

Lupus is a chronic autoimmune disease where the immune system generates antibodies that attack various organs such as kidneys, brain, heart, lungs, blood, skin and joints.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BMS-986165 is a potent and selective tyrosine kinase 2 inhibitor being developed to suppress pathways implicated in lupus.

The companies will assess the drug candidate in approximately 360 subjects during a global, multi-centre, randomised, placebo-controlled, double-blind Phase II clinical trial.

Expected to be completed in 2020, the trial will compare the safety and efficacy of orally administered BMS-986165 with placebo.

“Early results to date indicate that BMS-986165 may be a promising oral therapy for people with lupus.”

The primary outcome of the trial is the proportion of patients that meet response criteria for SLE Responder Index.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BMS development team lead John Throup said: “Early results to date indicate that BMS-986165 may be a promising oral therapy for people with lupus.

“Lupus Therapeutics has assembled a Network of world class investigators that are well-positioned to help us assess the potential of BMS-986165 in this disease.”

BMS will fund the trial and work with Lupus Therapeutics to identify sites within the Lupus Clinical Investigators Network (LuCIN) in the US to participate in the trial.

LuCIN has been established for fast and cost-effective testing of potential new drugs and approaches to diagnose and monitor response to therapy.